The shortage of generic chemotherapy drugs cisplatin and carboplatin that began in early 2023 did not increase short-term mortality rates among people with advanced cancer, according to results of a cohort study.The analysis included data from 11,797 adults with advanced solid cancers who began first-line treatment during a 1-year interval before the shortage (Feb. 1, 2022, to Feb. 9, 2023) or a